Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

Financial Reports

Delisting from ASX Official List

March 31, 2021February 26, 2021

Delisting from Official List

Categories ASX Announcements, Financial Reports

Appendix 4C – quarterly

March 31, 2021February 1, 2021

Appendix 4C – quarterly

Categories ASX Announcements, Financial Reports

4C Commentaries and Management Updates

January 14, 2021May 1, 2020

4C Commentaries and Management Updates

Categories ASX Announcements, Financial Reports

Appendix 4C – quarterly

April 30, 2020

Appendix 4C – quarterly

Categories ASX Announcements, Financial Reports

Appendix 4C – Commentaries & Management Updates

February 6, 2020

Appendix 4C Commentaries & Management Updates

Categories ASX Announcements, Financial Reports

Quarterly Appendix 4C – December 2019

January 1, 2020

Quarterly Appendix 4C

Categories ASX Announcements, Financial Reports

Quarterly Appendix 4C

November 1, 2019

Quarterly Appendix 4C

Categories ASX Announcements, Financial Reports

Annual Report – 2019

October 3, 2019

Annual Report 2019

Categories ASX Announcements, Financial Reports

Quarterly Appendix 4C and Business updates

September 9, 2019

Quarterly Appendix 4C and Business updates

Categories ASX Announcements, Financial Reports

Quarterly Appendix 4C and Business updates

April 30, 2019

Quarterly Appendix 4C and Business updates

Categories ASX Announcements, Financial Reports
Post navigation
Older posts
Page1 Page2 … Page4 Next →

Recent Posts

  • Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
  • Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
  • Operational Updates – February 2024
  • Operational Updates – October 2023
  • Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com
SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings